Bjelakovic Goran, Nikolova Dimitrinka, Simonetti Rosa G, Gluud Christian
Copenhagen Trial Unit, Centre for Clinical Intervention Research,, Department 3344, Rigshospitalet, Copenhagen University Hospital,, Blegdamsvej 9, Copenhagen, Denmark, DK-2100.
Cochrane Database Syst Rev. 2008 Jul 16(3):CD004183. doi: 10.1002/14651858.CD004183.pub3.
Oxidative stress may cause gastrointestinal cancers. The evidence on whether antioxidant supplements are effective in preventing gastrointestinal cancers is contradictory.
To assess the beneficial and harmful effects of antioxidant supplements in preventing gastrointestinal cancers.
We identified trials through the trials registers of the four Cochrane Review Groups on gastrointestinal diseases, The Cochrane Central Register of Controlled Trials in The Cochrane Library (Issue 2, 2007), MEDLINE, EMBASE, LILACS, SCI-EXPANDED, and The Chinese Biomedical Database from inception to October 2007. We scanned reference lists and contacted pharmaceutical companies.
Randomised trials comparing antioxidant supplements to placebo/no intervention examining occurrence of gastrointestinal cancers.
Two authors (GB and DN) independently selected trials for inclusion and extracted data. Outcome measures were gastrointestinal cancers, overall mortality, and adverse effects. Outcomes were reported as relative risks (RR) with 95% confidence interval (CI) based on random-effects and fixed-effect model meta-analysis. Meta-regression assessed the effect of covariates across the trials.
We identified 20 randomised trials (211,818 participants), assessing beta-carotene (12 trials), vitamin A (4 trials), vitamin C (8 trials), vitamin E (10 trials), and selenium (9 trials). Trials quality was generally high. Heterogeneity was low to moderate. Antioxidant supplements were without significant effects on gastrointestinal cancers (RR 0.94, 95% CI 0.83 to 1.06). However, there was significant heterogeneity (I(2) = 54.0%, P = 0.003). The heterogeneity may have been explained by bias risk (low-bias risk trials RR 1.04, 95% CI 0.96 to 1.13 compared to high-bias risk trials RR 0.59, 95% CI 0.43 to 0.80; test of interaction P < 0.0005), and type of antioxidant supplement (beta-carotene potentially increasing and selenium potentially decreasing cancer risk). The antioxidant supplements had no significant effects on mortality in a random-effects model meta-analysis (RR 1.02, 95% CI 0.97 to 1.07, I(2) = 53.5%), but significantly increased mortality in a fixed-effect model meta-analysis (RR 1.04, 95% CI 1.02 to 1.07). Beta-carotene in combination with vitamin A (RR 1.16, 95% CI 1.09 to 1.23) and vitamin E (RR 1.06, 95% CI 1.02 to 1.11) significantly increased mortality. Increased yellowing of the skin and belching were non-serious adverse effects of beta-carotene. In five trials (four with high risk of bias), selenium seemed to show significant beneficial effect on gastrointestinal cancer occurrence (RR 0.59, 95% CI 0.46 to 0.75, I(2) = 0%).
AUTHORS' CONCLUSIONS: We could not find convincing evidence that antioxidant supplements prevent gastrointestinal cancers. On the contrary, antioxidant supplements seem to increase overall mortality. The potential cancer preventive effect of selenium should be tested in adequately conducted randomised trials.
氧化应激可能导致胃肠道癌症。关于抗氧化剂补充剂在预防胃肠道癌症方面是否有效的证据相互矛盾。
评估抗氧化剂补充剂在预防胃肠道癌症中的有益和有害作用。
我们通过四个Cochrane胃肠道疾病综述小组的试验注册库、Cochrane图书馆中的Cochrane对照试验中心注册库(2007年第2期)、MEDLINE、EMBASE、LILACS、SCI-EXPANDED以及中国生物医学数据库,检索了从数据库建立至2007年10月的试验。我们浏览了参考文献列表并联系了制药公司。
比较抗氧化剂补充剂与安慰剂/无干预措施,以研究胃肠道癌症发生率的随机试验。
两位作者(GB和DN)独立选择纳入试验并提取数据。结局指标为胃肠道癌症、总死亡率和不良反应。结局以基于随机效应和固定效应模型荟萃分析的相对风险(RR)及95%置信区间(CI)报告。荟萃回归评估了各试验中协变量的影响。
我们确定了20项随机试验(211,818名参与者),评估了β-胡萝卜素(12项试验)、维生素A(4项试验)、维生素C(8项试验)、维生素E(10项试验)和硒(9项试验)。试验质量总体较高。异质性为低到中度。抗氧化剂补充剂对胃肠道癌症无显著影响(RR 0.94,95% CI 0.83至1.06)。然而,存在显著异质性(I² = 54.0%,P = 0.003)。这种异质性可能由偏倚风险(低偏倚风险试验RR 1.04,95% CI 0.96至1.13,而高偏倚风险试验RR 0.59,95% CI 0.43至0.80;交互作用检验P < 0.0005)以及抗氧化剂补充剂的类型(β-胡萝卜素可能增加癌症风险,硒可能降低癌症风险)来解释。在随机效应模型荟萃分析中,抗氧化剂补充剂对死亡率无显著影响(RR 1.02,95% CI 0.97至1.07,I² = 53.5%),但在固定效应模型荟萃分析中显著增加了死亡率(RR 1.04,95% CI 1.02至1.07)。β-胡萝卜素与维生素A联合使用(RR 1.16,95% CI 1.09至1.23)以及与维生素E联合使用(RR 1.06,95% CI 1.02至1.11)显著增加了死亡率。皮肤发黄和嗳气增加是β-胡萝卜素的非严重不良反应。在五项试验(四项偏倚风险高)中,硒似乎对胃肠道癌症的发生有显著有益作用(RR 0.59,95% CI 0.46至0.75,I² = 0%)。
我们未找到令人信服的证据表明抗氧化剂补充剂可预防胃肠道癌症。相反,抗氧化剂补充剂似乎会增加总死亡率。硒潜在的癌症预防作用应在充分开展的随机试验中进行检验。